You are here:
Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates
Citation:
Clewell, R., J. Leonard, C. Nicolas, J. Cambpell, M. Yoon, A. Efremenko, P. McMullen, M. Andersen, H. Clewell, K. Phillips, AND C. Tan. Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. TOXICOLOGY IN VITRO. Elsevier Science Ltd, New York, NY, 66:104855, (2020). https://doi.org/10.1016/j.tiv.2020.104855
Impact/Purpose:
The utility of Aggregate Exposure Pathway (AEP) and Adverse Outcome Pathway (AOP) framework concepts to inform risk assessment was explored using a case study approach. This case study focused on conducting a cumulative risk assessment for two common phthalate esters: di(2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate (DnBP). To this end, an AEP was developed to support the estimation of aggregate exposures to multiple phthalates with common toxicological responses.
Description:
Advancements in measurement and modeling capabilities are providing unprecedented access to estimates of chemical exposure and bioactivity. With this influx of new data, there is a need for frameworks that help organize and disseminate information on chemical hazard and exposure in a manner that is accessible and transparent. A case study approach was used to demonstrate integration of the Adverse Outcome Pathway (AOP) and Aggregate Exposure Pathway (AEP) frameworks to support cumulative risk assessment of co-exposure to two phthalate esters that are ubiquitous in the environment and that are associated with disruption of male sexual development in the rat: di(2-ethylhexyl) phthalate (DEHP) and di-n-butyl phthalate (DnBP). A putative AOP was developed to guide selection of an in vitro assay for derivation of bioactivity values for DEHP and DnBP and their metabolites. AEPs for DEHP and DnBP were used to extract key exposure data as inputs for a physiologically based pharmacokinetic (PBPK) model to predict internal metabolite concentrations. These metabolite concentrations were then combined using in vitro-based relative potency factors for comparison with an internal dose metric, resulting in an estimated margin of safety of ~13,000. This case study provides an adaptable workflow for integrating exposure and toxicity data by coupling AEP and AOP frameworks and using in vitro and in silico methodologies for cumulative risk assessment.
URLs/Downloads:
DOI: Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates